Radiopharmaceutical Pluvicto, Locametz, Lutathera and Netspot Injections

The Defense Health Agency’s Healthcare Contracting Division – West is issuing a Notice of Intent to award a sole source Blanket Purchase Agreement under solicitation HT941026N0009 for the procurement of four specialized radiopharmaceutical injections—Pluvicto, Locametz, Lutathera, and Netspot—to support the Nuclear Medicine Division at Naval Medical Center San Diego and multiple other military treatment facilities under its jurisdiction. The contract, intended to run from January 5, 2026, through January 4, 2031, is justified under FAR 13.501(a) and FAR 13.106-1(b)(1)(i) due to the exclusive availability of these products from Novartis Pharmaceuticals Corporation, the sole manufacturer with the requisite regulatory approvals and proprietary formulations. The acquisition is conducted under the existing National Pharmaceutical Center Federal Supply Schedule contract 36F79720D0180, leveraging its pre-negotiated pricing and terms, though no detailed line-item pricing, quantities, or contract value are disclosed in this pre-solicitation notice. Each product is identified by its National Drug Code, and while the document acknowledges the necessity of compliance with FDA and USP standards for pharmaceutical integrity, it does not specify detailed packaging, preservation, labeling, or barcoding protocols beyond the inclusion of NDC identifiers. The procurement process includes a 30-day window for interested parties to submit capability statements challenging the sole source determination, with submissions required to be no more than six pages in length, in either Microsoft Word or Adobe PDF format, and sent electronically by the deadline of December 9, 2026, to the designated contracting point of contact. No competitive evaluation factors, quality inspection criteria beyond regulatory compliance, or specific delivery terms such as FOB or invoicing procedures are outlined, as the acquisition is non-competitive by design. The Defense Health Agency retains full responsibility for product acceptance at point of delivery in San Diego, California, and the contracting office located in Camp Pendleton, California, serves as the administrative hub, with Cha-on P. Gordon identified as the primary liaison for challenges. Novartis Pharmaceuticals Corporation is confirmed as the only qualified vendor through its UEI NG61ZA8TADW3 and CAGE code 04520, with its status as other than small firmly established under NAICS code 325412. No set-aside provisions,